Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response Syndrome
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Sepsis is a life-threatening organ dysfunction caused by the maladjusted response of the host
to infection. It is a clinical syndrome with high mortality. Studies have confirmed that many
cytokines play a vital role in the pathogenesis of sepsis. Ulinastatin (UTI) is a
glycoprotein that exists in human blood and can be isolated and purified from human urine. It
is a broad-spectrum protease inhibitor. Previous studies have shown that Ulinastatin may have
the effect of treating sepsis.
120 septic patients with systemic inflammatory response syndrome would be recruited and
randomly assigned to the ordinary dose group, high dose group and placebo control group
according to the ratio of 1:1:1.
The trial will be followed up on days 0, 1, 3, 5, 7 and 28. Sofa on day 7 compared with
baseline and all-cause mortality on day 28 were investigated to explore the efficacy of
ulinastatin in the treatment of adult sepsis patients with systemic inflammatory response
syndrome.